Home
|
Press
|
Events
|
Eshare
Sign in
/
Register
0
Shopping Cart
X
Close
My Products (0 items)
My shopping cart is empty.
.
Sign in
/
Register
X
Close
Login/Register
Email
Password
INDUSTRIES
Agriculture
Chemicals
Food & Feed
Pesticides
Titanium Dioxide (TiO2)
Dairy Products
Full Industry List
ONLINE DATABASE
PRODUCTS & SERVICE
Products' Introduction
Industrial Reports
Newsletters
Market Data
Content Byte
Agrochemical Regulatory
Customized solutions
IMPACT FACTOR
MARKET NEWS
Agriculture
Chemicals
Food & Feed
Other
ABOUT
About CCM
Why CCM?
CCM Story
CCM Clients
Events
Career
Company news
CONTACT
Home
Product
Newsletters
>
亿帆医药研发的药物获得药物临床试验
Read online
亿帆医药研发的药物获得药物临床试验
6月14日,亿帆医药股份有限公司(亿帆医药)发布关于获得药物临床试验通知的公告,公告中表示,控股公司健能隆医药技术(上海)有限公司(上海健能隆)于近日收到中国食品药品监督管理总局(CFDA)、澳大利亚Alfred医院伦理委员会签发的药物临床试验批件。 获得药物临床试验的药物分别是重组人粒细胞集落刺激因子-Fc融合蛋白注射液(F-627)和重组抗EpCAM-CD3 抗体注射液(A-337)。其中F-627用于肿瘤放、化疗引起的嗜中性粒细胞减少症,2016年,F-627对应的G-CSF同类产品全球...
Vitamins China E-News 201706 (Chinese version)
Add to DIY report
Select whole article
I haven't create reports,
create a new report
right now!
Recommend Newsletters
Crop Farming in China
2016/05/31
More>>
Report on Glyphosate Business Opportunities Worldwide
2016/07/27
More>>
Specialised Control and Prevention of Pests and Diseases for Crops in China
2016/07/12
More>>
Loading...